Introduction
The Gram-positive coccobacillus Rhodococcus equi is a causative agent of pyogranulomatous pneumonia in foals less than six months in age and in immunocompromised people (Weinstock and Brown, 2002; Giguere et al., 2011; Vazquez-Boland et al., 2013) . Cattle and swine are also occasional hosts but disease presentation in these species is different and typically manifests as respiratory lymph node abscessation and sub-maxillary lymphadenitis respectively (Flynn et al., 2001; Komijn et al., 2007; Valero-Rello et al., 2015) . Delayed type hypersensitivity testing of horses has determined that exposure to R. equi is widespread. Disease, however, is either sporadic or endemic depending on the horse farm (Barton and Hughes, 1984; Takai, 1997) . While a significant portion of subclinical disease resolves naturally, the unrestrained use of antibiotics on some horse farms has led to the emergence of antimicrobial resistant strains of the bacterium, complicating treatment during disease progression (Giguere, 2017) . Additionally, the rise in human immunocompromised populations, whether it was from chemotherapy or HIV, has allowed the bacterium to become a relevant opportunistic pathogen of humans (Weinstock and Brown, 2002) .
R. equi exposure of foals typically occurs through inhalation of aerosolized bacteria from contaminated soil, wherein the bacterium is introduced to the lower airway (Muscatello et al., 2006) . Delivery of the bacterium to the lungs allows alveolar macrophages to recognize and phagocytose the bacterium. Thereafter, the macrophage will attempt to kill the bacterium through a variety of antimicrobial mechanisms, including the production of reactive oxygen and nitrogen species, activation of hydrolytic enzymes, generation of an acidified vacuolar compartment and depletion of essential nutrients (Flannagan et al., 2009) . Despite these tactics, R. equi is able to survive and replicate within macrophages of susceptible hosts, designating the bacterium a facultative intracellular pathogen (Hondalus and Mosser, 1994) .
Initial studies indicated that there are both virulent and avirulent strains of R. equi, differing in the possession of a virulence-associated plasmid (Giguere et al., 1999) . Subsequent work has shown that the type of virulence plasmid carried by disease-causing strains of R. equi is host specific; wherein pVapA is the plasmid type carried by R. equi isolates infecting equine and is the most studied of the virulence plasmid types (Ocampo-Sosa et al., 2007) . pVapB and pVapN comprise the remainder of the sequenced virulence plasmids and are carried by R. equi strains infecting swine and bovine species respectively (Valero-Rello et al., 2015) . Human infection can arise from R. equi carrying any of the aforementioned virulence associated plasmids, but the most commonly detected pathogen is R. equi harboring the pVapB type virulence plasmid (Ocampo-Sosa et al., 2007) . The ability of multiple R. equi strains harboring different virulence plasmids to cause disease in immunocompromised humans confirms the opportunistic capacity of this bacterium. Sequence analysis of these virulence plasmids revealed the presence of four common regions known as the conjugation, replication, unknown function and the virulence or pathogenicity island (PAI) regions (Letek et al., 2008; Valero-Rello et al., 2015) . Within the PAI region of these plasmids, members of a novel gene family, the vap (virulence associated protein) family reside. Deletion of the plasmid PAI renders the bacterium incapable of replication in macrophages (Coulson et al., 2010) . Further experimentation on the pVapA type virulence plasmid has shown that, of the twenty open reading frames present in the PAI, only three are required for intramacrophage replication: virR, virS and vapA (Jain et al., 2003; Coulson et al., 2015; Valero-Rello et al., 2015) .
virR and virS encode for transcriptional regulators crucial for the expression of vapA as well as a number of other genes found on both the virulence-associated plasmid and the R. equi chromosome. The vapA gene produces the highly immunogenic protein, virulence associated protein A (VapA) (Takai et al., 1991; Jain et al., 2003; Coulson et al., 2015; Kakuda et al., 2015) . There are five other open reading frames located in the pVapA PAI encoding for proteins with a high degree of identity to vapA: vapG, vapH, vapC, vapD and vapE (Letek et al., 2008) . Targeted deletion studies of each of these vap genes have determined that deletion of vapA alone attenuates the bacterium's ability to replicate within macrophages (Jain et al., 2003; Coulson et al., 2010; Wang et al., 2014) . Therefore, VapA activity does not appear to be shared among these related Vap homologues even though many of these Vap-family proteins appear to be expressed during R. equi infection (Byrne et al., 2001; Hooper-McGrevy et al., 2003; Jacks et al., 2007) . While the mechanism of action of VapA has yet to be discerned, it has been determined that VapA is localized on the surface of R. equi, giving it the capability to directly interact with the host (Takai et al., 1992) . Studies have shown that virulent R. equi reside within an enlarged neutral compartment in the macrophage and that the presence of vapA inhibits the acidification of the R. equi containing vacuole (RCV), thereby supporting the intracellular survival of the bacterium (Fernandez-Mora et al., 2005; Toyooka et al., 2005; von Bargen et al., 2009) .
Direct visualization of R. equi after phagocytic uptake has determined that the recruitment of early trafficking markers to the bacteria-laden phagosome is unaffected. The early endosomal markers Rab5 and early endosomal antigen 1 (EEA1) are gained and lost by the RCV in a timely manner. Late endosomal markers lysobisphosphatidic acid, Rab7, and lysosomal-associated membrane proteins (LAMP) 1 and 2 increase subsequently, suggesting that maturation of these endosomal compartments to late endosomes proceeds unhindered by the presence of the bacterium (Fernandez-Mora et al., 2005) . The two aberrant phenotypes associated with R. equi infection of macrophages are the lack of acidification of, and replication within, an enlarged phagosomal compartment (Fernandez-Mora et al., 2005; Toyooka et al., 2005; von Bargen et al., 2009) .
Sequence characterization of the Vap proteins suggests that they can be broken into three domains, designated as the signal sequence, disordered and conserved domains (Letek et al., 2008) . Molecular work on the Vap proteins has determined the protein structure of the conserved domain of VapG, VapD and VapB; VapB is a virulence associated protein located in the PAI of pVapB (Takai et al., 1996; Makrai et al., 2002; Geerds et al., 2014; Okoko et al., 2015; ValeroRello et al., 2015; Whittingham et al., 2014) . Solved structures resolved an eight stranded anti-parallel b-barrel connected by an a-helix for each of the preceding proteins, although the solved structures could not provide much insight into the function of these Vaps (Geerds et al., 2014; Whittingham et al., 2014; Okoko et al., 2015) . Attempts to crystallize VapA have been unsuccessful, but it is presumed that the protein obtains a similar structure to the other Vaps due to high sequence homology. More recent work on endocytosed recombinant VapA has determined that the protein does not directly inhibit acidification but can reduce hydrolytic capacity and cause endolysosomal swelling of normal rat kidney cells; however, a mechanism for how VapA alters cellular trafficking remains to be determined (Rofe et al., 2017) .
This study further characterizes VapA, the major virulence determinant of Rhodococcus equi isolates carrying pVapA. Experiments focused on localizing the protein during both macrophage infection and in vitro expression in yeast show a distinct membrane-binding activity of VapA, which may be critical for its ability to alter endolysosomal traffic in host cells during infection. Additionally, the ability of rVapA to bind to liposomes of varying lipid composition was analyzed, and provides evidence that membrane phosphatidic acid is a ligand for VapA.
Results
Recombinant VapA complements the intramacrophage replication defect of an R. equi strain lacking vapA To survive and replicate intracellularly, R. equi harboring the pVapA-type virulence plasmid requires only the activity of vapA, and two transcriptional regulators, virR and virS, all residing within the plasmid-borne PAI (Coulson et al., 2015) . Since VapA appears to be the only pVapA-encoded Vap family protein essential for the growth of R. equi in macrophages (Jain et al., 2003) , and considering a recent study that showed that VapA could directly alter lysosomal activity when endocytosed by the normal rat kidney cell line (Rofe et al., 2017) , we assessed whether macrophages pre-treated with purified recombinant VapA lacking the putative N-terminal signal sequence, rVapA , could rescue the intramacrophage replication defect of R. equi DvapA. It is important to note that this fragment of the VapA protein is known to be functional, as mature VapA lacks the first 31 N-terminal amino acids (Tan et al., 1995) . In these experiments, bacterial intracellular growth in the J774A.1 macrophage cell line was followed over time by traditional lysis and plating of infected monolayer lysates. As anticipated, intracellular bacterial loads of wild type R. equi (103S) increased 17-fold over 48 h. This was in contrast to bacteria lacking the pVapA-type virulence plasmid (103 P-), whose growth was reduced 10-fold over the same time frame (Fig. 1A and B) . Similar to 103 P-, the wild type R. equi strain lacking vapA (DvapA) was unable to replicate intracellularly, although intracellular bacterial loads persisted over the course of the infection (Fig. 1A and B) . Strikingly, the addition of rVapA 32-189 restored the ability of the DvapA strain to , then infected with the indicated R. equi strain. Each experimental condition was performed in triplicate per infection; n 5 3. Symbols denote the mean number of bacteria observed and the bars denote the mean bacterial fold change. Error bars represent the standard deviation using a two-way ANOVA by way of the Holm-Sidak test. (A and C) Letters to the right of each curve denote statistical significance; the same letter signifies no statistical difference, while different letters signify statistical difference at P 0.05. B and D) ns, not significant; (*) 5 P < 0.05; (**) 5 P < 0.01; (***) 5 P < 0.001.
replicate in a dose-dependent manner, wherein macrophages pre-treated with 100 nM of rVapA 32-189 could replicate to levels comparable to that of the wild type strain ( Fig. 1A and B (vapG, vapH, vapE, vapC and vapD) located in the PAI of pVapA, VapG displays the highest sequence identity to VapA at 48%, and is known to have high mRNA expression levels during R. equi infection of foals (Jacks et al., 2007; Letek et al., 2008; Okoko et al., 2015; ValeroRello et al., 2015) . Despite these characteristics, purified recombinant VapG 27-172 was unable to rescue the replication defect of DvapA bacteria ( Fig. 1C and D) .
Isolates of R. equi that harbor a pVapB-type plasmid contain six distinct vap genes (vapJ, vapK1, vapL, vapK2, vapM and vapB) (Letek et al., 2008; Valero-Rello et al., 2015) . Because of the high sequence identity (78%) between the VapB and VapA proteins, it has been proposed that the VapB protein in R. equi strains harboring pVapB would be functionally equivalent to VapA during pathogenesis (Letek et al., 2008) . Despite this, a recent report speculates that VapK1/K2, with 59% identity to VapA, is the functional equivalent of VapA in pVapB-carrying R. equi strains (Letek et al., 2008; Valero-Rello et al., 2015) . Interestingly, in support of the latter, we found that while the addition of rVapB was unable to reverse the intracellular replication defect of DvapA, rVapK2 32-202 addition resulted in a 10-fold increase of DvapA bacterial loads 48 h postinfection ( Fig. 1C and D) . Importantly, this increase was in-line with the overall magnitude of intracellular replication displayed by that of the wild type pVapB-carrying R. equi strain 33705 ( Fig. 1C and D) , although the overall extent of bacterial replication was reduced when compared to the growth displayed by the DvapA strain in the presence of rVapA . To assess whether the lack of effect of rVapG and rVapB could be explained by improper folding of the recombinant proteins, all of the recombinant Vap proteins used in these studies were subjected to Proteinase K digestion and analyzed by gel electrophoresis, as previously performed by Geerds and coworkers, who described the presence of a properlyfolded 12 kDa core domain of VapA and VapB that was resistant to proteolytic degradation (Geerds et al., 2014) . On exposure to Proteinase K digestion, we detected this Proteinase K-resistant core domain in each of the rVaps used in this study; this proteaseresistant fragment was lost on the denaturation of the protein in SDS (Supporting Information Fig. 1 ). These data suggest that each of the Vap proteins tested was appropriately folded and that the inability of rVapB or rVapG on the intracellular survival of a nonpathogenic E. coli strain. As expected, the nonpathogenic E. coli strain was unable to replicate or persist in J774A.1 cells, with intracellular bacterial loads reduced by 80% at 12 hours post infection ( Fig. 2A and B) . On preincubation of macrophages with rVapA , however, the survival of E. coli was greatly enhanced and bacterial numbers were only reduced by 40% at 12 h post infection ( Fig. 2A and B) . In contrast, macrophages incubated with rVapG were not significantly different from untreated macrophages in their ability to kill E. coli under these conditions ( Fig. 2A and B) . To support the intracellular persistence of a nonpathogenic bacterium, it is likely that rVapA 32-189 directly alters host phagolysosomal function.
Localization of VapA during R. equi infection shows the protein at the bacterial surface and the RCV membrane
Because rVapA 32-189 appeared to be able to directly modulate the activity of host phagolysosomal compartments, we sought to localize R. equi-produced VapA over the course of an infection. For these studies, we utilized murine bone marrow-derived macrophages
VapA of R. equi binds phosphatidic acid 431 (BMDMs) as the host for R. equi. Both wild type 103S and DvapA R. equi strains harboring a GFP expression plasmid were utilized to locate bacteria during infection of BMDM monolayers, and intracellular bacterial loads were measured via direct visualization and enumeration. As expected, the 103S-GFP wild type strain was capable of replicating intracellularly over 72 h, and the DvapA-GFP strain was cleared from these macrophages over the same timeframe ( Fig. 3A and B). As previously observed, supplementation with exogenous rVapA restored the ability of the DvapA-GFP strain to survive and replicate intracellularly ( Fig. 3A and B). Of note, these results ( Fig. 3B ) likely underestimate the total number of intracellular bacteria because of the clumping nature of R. equi and the fact that macrophages containing more than 10 organisms were quantified as containing only 10 bacteria. Therefore, the number of macrophages containing ten or more bacteria was also followed over time. After 72 h, 35 of 200 macrophages infected with 103S harbored 10 intracellular bacteria, compared to 1 macrophage infected with the DvapA strain. In the presence of exogenous rVapA , almost 80 of 200 macrophages assessed contained 10 or more DvapA bacteria, thus directly confirming the ability of rVapA to support the intracellular replication of DvapA R. equi (Fig. 3C ).
Visualization of monolayers infected with 103S R. equi showed the presence of VapA at the bacterial surface throughout the course of infection (Fig. 3A) . After 48 h, however, in addition to remaining on the surface of the bacterium, we found that VapA was also observed to accumulate on the membrane of the R. equi-containing vacuole (RCV) (Fig. 3A , arrows and insets). In DvapA-infected monolayers supplemented with rVapA , the recombinant protein displayed a highly punctate staining pattern at 1 h post-infection, reminiscent of vesicular packaging on endocytic or pinocytotic uptake (Fig. 3A, T1 ). After 48 h, rVapA 32-189 appears to accumulate around and within RCVs, suggesting that not only is rVapA 32-189 eventually trafficked to bacterialaden compartments within these cells, but that its activity is needed within (or on) the RCV to support the replication of the R. equi DvapA strain. Taken together, these images indicate that VapA likely functions in the lumen of the RCV, and that VapA may begin to associate with the membrane of bacteria-laden host vacuoles by 48 h after infection.
VapA localizes to the yeast plasma membrane
Because of the discovery that VapA appears to localize to the limiting membrane of mature RCVs during R. equi infection, we decided to exploit a model eukaryotic system to aid in characterizing the cellular localization of the various Vap-family proteins. The budding yeast Saccharomyces cerevisiae is a robust model system for essential eukaryotic processes and has often been used to study the biochemical activities of secreted bacterial effector proteins that alter eukaryotic physiology (Siggers and Lesser, 2008; Botstein and Fink, 2011) . N- , VapB and VapK2 32-202 were constructed in the yeast GFP expression vector pGO35 (Burd and Emr, 1998; Odorizzi et al., 1998) , and protein expression of each of these constructs in yeast was examined via immunoblot ( Fig. 4A ). Each GFP-Vap construct, with the exception of GFP-VapG , generated the expected 44 kDa band on exposure with the polyclonal and cross-reactive anti-VapA antibody. Subsequently, the localization of each GFP-Vap fusion (other than GFP-VapG) within S. cerevisiae was examined. Expression of GFP alone showed a diffuse cytosolic staining, as expected (Fig. 4B) . However, expression of either GFP-tagged VapA construct (VapA or VapA ) resulted in a striking localization of GFP to the yeast plasma membrane. In fact, plasma membrane localization of GFP was observed in 100% of the GFP-VapA expressing yeast cells (Fig. 4C) . In contrast, yeast expressing either or GFP-VapB , showed a marked decrease in the amount of GFP localized to the plasma membrane (Fig. 4B) , were visualized for GFP localization via fluorescence microscopy. Bar 5 5 m. C. Quantification of GFP localization from yeast strains imaged in (A); Cells with clear accumulation of GFP-Vap protein at the plasma membrane was counted as 'plasma membrane', diffuse GFP staining of the cytoplasm with no plasma membrane localization was counted as 'cytoplasm;' all other morphologies were counted as 'other'. 100 yeast cells were counted per experimental condition, bars denote the mean percent of cells displaying a particular Vap localization pattern. Error bars represent the standard deviation using a two-way ANOVA by way of the Holm-Sidak test, and significance pertaining to the difference in plasma membrane localization of GFP-Vap proteins is indicated. n 5 3; ns, not significant and (***) 5 P 0.001. co-floatation (Fig. 5A ). In contrast, rVapA 32-189 was found to bind to liposomes containing 20% PA when incubations were performed at a pH of 5.5; a minor interaction with PS-containing liposomes was also observed (Fig. 5B) . Furthermore, rVapA 32-189 bound PAcontaining liposomes in a concentration-dependent manner (Fig. 5C ). Thus, rVapA 32-189 appears to bind to some negatively-charged lipids under acidic conditions, with a preference for membranes containing phosphatidic acid. Finally, we assayed each of the other closely related Vap proteins isolated in this study ) for their ability to interact with membranes containing phosphatidic acid. Results showed that none of these Vaps could appreciably interact with these liposomes (Fig. 5D) . Therefore, the interaction of VapA with phosphatidic acid appears to be unique among the Vap-family proteins tested.
R. equi resides in LAMP1-negative vesicles in the presence of VapA
Because the existence of VapA at the phagosomal membrane could impact host phagolysosomal trafficking, we followed the presence of the late endosomal/ lysosomal marker LAMP1 (lysosomal-associated membrane protein 1) during the course of macrophage infection (Vieira et al., 2002; Flannagan et al., 2009) . It has been reported that RCVs associate with LAMP1 up to twenty-four hours post infection, and it has been presumed that wild type R. equi remain in a late endosome-like compartment by inhibiting the fusion of bacterial-containing vesicles with degradative lysosomes (Fernandez-Mora et al., 2005) . Using the GFPexpressing 103S and immunofluorescence staining for LAMP1, we similarly found R. equi-containing vesicles to be associated with LAMP1 up to twenty-four hours post infection, and noted that the vesicular membranes were closely associated with individual bacteria (Fig. 6 , 103S, T24). We extended these observations and at 48h post infection, when bacterial loads were high, we noted that the RCV became enlarged and LAMP1 was no longer associated with R. equi-containing vacuoles (Fig. 6, 103S, T48 ). Interestingly, LAMP1 appeared to be excluded from VapA-positive membranes (Fig. 6 , 103S, insets), which continued until at least 72 h post infection (Fig. 6B) . Furthermore, there was a noticeable increase in LAMP1 staining of macrophages harboring replicating bacteria than the surrounding uninfected cells. In contrast, RCVs containing DvapA bacteria were found to be associated with LAMP1 throughout the course of infection, suggesting delivery of these mutant R. equi to the degradative lysosome and a lack of intracellular replication (Fig. 6, DvapA) . Contrastingly, in the presence of 100 nM rVapA , DvapA bacteria were found to be located in both LAMP1-positive and -negative compartments at 48-72 h post infection (Fig. 6 , DvapA 1 rVapA, insets). Although the RCV was never found to be enlarged under these conditions, as in the wild type infections, intracellular bacterial loads increased in spite of some overlap with LAMP1-containing vesicles. Taken together, these data suggest that the presence of VapA at the RCV membrane is associated with altered phagolysosomal maturation or altered endolysosomal trafficking pathways in macrophages, and that LAMP1 displacement away from VapA-producing R. equi occurs beyond twenty-four hours post infection.
Discussion
Herein, we show that exogenous addition of rVapA protein to macrophage monolayers both reversed the intracellular growth defect of R. equi DvapA bacteria and supported the persistence of nonpathogenic E. coli, highlighting the ability of the major virulence determinant of R. equi, VapA, to broadly inhibit the killing capacity of macrophages ( Figs. 1 and 2 ). Our work determined that soluble rVapA 32-189 at 100 nm (1.7 mg ml 21 ) was sufficient to restore intramacrophage replication of DvapA to wild type levels. Our findings are supported by those of another group who very recently described the rescue of DvapA growth in macrophages in the presence of 100 ug ml 21 soluble rVapA (Sangkanjanavanich et al., 2017) . The group also reported that addition of rVapA allowed for the intracellular growth of an avirulent plasmid-cured strain of R. equi, 103 P-. The latter was a surprising result, given it is well-established that expression of wild type levels of VapA alone by virulence plasmid-free R. equi is not sufficient to promote intramacrophage replication (Giguere et al., 1999; Coulson et al., 2015) , although Sangkanjanavanich and colleagues used at least 50-fold more rVapA than we found is required to support the intracellular replication of DvapA R. equi in this study. Interestingly, we also found that a related Vap protein encoded on the pVapB-type plasmid carried by some R. equi strains (e.g., 33705), rVapK2 , showed a similar capacity to restore the growth of DvapA bacteria in macrophages, albeit to a lesser degree (Fig. 1) . No other recombinant Vap protein tested shared this activity, suggesting that the ability to alter macrophage antimicrobial capabilities is specific for VapA and its functional homologues (like VapK2) across R. equi strains harboring different virulence plasmids.
To better understand VapA's mechanism of action, we sought to observe the localization of VapA during extended R. equi macrophage infection. While previous in vitro experimentation has determined that VapA is located on the surface of the bacterium (Takai et al., 1992) , to our knowledge, this is the first time in which this localization has been confirmed during macrophage infection. Strikingly, at 48 h post-infection, VapA was no longer solely confined to the bacterial surface, but also appeared at the membrane of the RCV (Fig. 3A) . The mechanism by which VapA is delivered to the RCV membrane is unknown, but reasoning suggests that active secretion of VapA from intracellular R. equi, release of VapA from shedding of the outer cell envelope from intracellularly replicating bacteria, degradation of some bacteria within the RCV, or delivery via an interaction between the bacterium and phagosomal membrane during initial phagocytic uptake are all viable possibilities. Byrne and coworkers previously described the secretion of VapC, VapD and VapE into R. equi culture supernatant, but could not detect VapA via immunoblot (Byrne et al., 2001) . While this demonstrates that R.equi does not secrete VapA across the outer lipid envelope into the supernatant during routine laboratory culture, it may be that signals within the intramacrophage environment triggers release of the protein from the bacterial surface. Some intracellular pathogens harbor type three (T3SS) and type 4 (T4SS) secretion systems allowing for bacterial effectors to be secreted into the cytoplasm of their host cell (Deng et al., 2017) . While genes encoding for a T3SS or classical T4SS are not present in R. equi, the R. equi virulence plasmid harbors genes required for the conjugal transfer of this plasmid (Tripathi et al., 2012) . It is unlikely that these genes are responsible for the secretion of VapA during infection, however, as this region is expendable for the proper localization of VapA on the surface of R. equi (Coulson et al 2010) . There is genetic evidence in R. equi for the presence of a type seven secretion system (T7SS; ESX) similar to Mycobacterium tuberculosis (Letek et al., 2010) . T7SS have been identified in a variety of Gram-positive organisms, where they participate in a wide number of functions including virulence and permitting the transport of substrates across the inner membrane and outer lipid envelope, or mycomembrane; however, these T7SS have not been shown to deliver substrates into the host cytoplasm. What role, if any, the T7SS may play in R. equi pathogenesis remains unknown at present.
This study provides the first experimental evidence showing VapA deposition on the membrane of the RCV during macrophage infection. VapA was not observed outside of the RCV (e.g., in the host cytosol) during macrophage infection with wild type R. equi. As a first step to better understand how the presence of VapA at the limiting membrane of the RCV might potentially affect phagolysosomal trafficking, we assessed the locations of both native VapA and of lysosomal-associated membrane protein 1 (LAMP1), found on late endosomes and lysosomes, over the course of macrophage infection (Fig. 6) . Previously published work has established that LAMP1 associates with RCVs containing virulent R. equi during the 24 h following uptake (Fernandez-Mora et al., 2005) . By extending this assessment further, however, we made a surprising observation: R. equi-containing vacuoles appear to exist in a mixed population during infection. Notably, enlarged RCVs with VapA at the limiting membrane were devoid of LAMP1, while RCVs that lacked VapA at the membrane were LAMP1 positive (Fig.  6 ). This finding suggests that VapA's presence at the RCV membrane is important in aiding the bacteria in avoiding destruction by the lysosomal compartment. While LAMP1 is initially gained, the RCV containing actively replicating bacteria can either displace, or avoid further accumulation of, LAMP1-containing endolysosomal vesicles (Fig. 6) (Figs. 5B-5D ), and to a much lesser extent, phosphatidylserine (PS) (Fig. 5B) . Interestingly, membrane PA concentrations in yeast are highest at the outer mitochondrial and plasma membranes, wherein both of these organelles also contain a high percentage of phosphatidylethanolamine (PE). Unique to the plasma membrane, however, is a high amount of PS along with PA and PE (Zinser et al., 1991) . Additionally, the more acidic environment (pH 5.5) used in these assays allowed rVapA 32-189 to bind PA as compared to neutral conditions (pH 7.4) ( Fig. 5A and B) . This increased interaction at a lower pH could be accounted for because of the lower charge PA holds in this environment (Shin and Loewen, 2011; Putta et al., 2016) . The fact that we found GFP-VapA able to bind the yeast plasma membrane in a near-neutral cytosolic pH may identify additional unknown lipid or protein ligands for VapA, which are required to increase the affinity of VapA for PA under these conditions.
VapA of R. equi binds phosphatidic acid 437
PA is an anionic glycerophospholipid that induces the formation of negative curvature in membranes (Kooijman et al., 2005) , and can participate in cellular signaling via both electrostatic and hydrophobic interactions with protein ligands (Lemmon, 2008) . During phagocytosis, phospholipase D actively generates PA in the phagocytic cup and post-phagocytic vesicles, which is required to properly deform the plasma membrane to generate the limiting membrane of the phagocytic vesicle (Corrotte et al., 2006) . This phagosomal pool of PA would provide VapA on the bacterial surface its host binding target on phagocytic uptake. That we observed rVapA 32-189 binding to PA-containing liposomes only in an acidic environment ( Fig. 5A and B) was interesting. Lack of lysosomal acidification has been well documented during R. equi infections using Lysotracker dye, which responds to a pH of 6.5 or lower by a shift in fluorescence intensity (Fernandez-Mora et al., 2005; Toyooka et al., 2005; von Bargen et al., 2009 ). Therefore, the VapA:PA interaction may occur during an initial acidification step during infection that is later hindered by the replicating bacterium. Support of this theory comes from the ability of R. equi to withstand acidic conditions and the upregulation of VapA during the bacterium's acid response (Benoit et al., 2001; Kakuda et al., 2014) . Previous measurements of phagosomal acidification during macrophage infections with R. equi have shown that while colocalization between the bacterium and Lysotracker dye is low, Lysotracker-positive vesicles are still detected early during the infection (Fernandez-Mora et al., 2005; Toyooka et al., 2005; von Bargen et al., 2009 ). These acidic vesicles may fuse with the nascent R. equi-containing phagosome, thus providing the trigger for VapA binding. Recently, it was discerned that rVapA supplemented normal rat kidney cells had high colocalization between Lysotracker dye and lysosomes but that the lysosomes had a lower hydrolytic capacity (Rofe et al., 2017) . Taken together, we can speculate that VapA is not directly altering phagosomal/lysosmal pH, but rather still-undescribed mechanisms downstream of VapA activity are required for R. equi to limit RCV acidification. Signaling mediated by PA is becoming better understood as an important means for cellular communication, and is implicated in the regulation of critical cellular events including vesicular trafficking, actin polymerization and respiratory burst (Fang et al., 2001; Lim et al., 2003; Corrotte et al., 2006; Wang et al., 2006; Frondorf et al., 2010; Schlam et al., 2013) . Phosphatidic acid is able to mediate the Akt-mTOR-S6K signaling cascade at each of the pathway components and may be a way in which the bacterium promotes intramacrophage growth (Fang et al., 2001; Lim et al., 2003; Wang et al., 2006; Frondorf et al., 2010) . Macrophages grown in PAsupplemented media activated the Akt-dependent signaling cascade, thus leading to the production of proinflammatory cytokines, nitric oxide and prostaglandin E2. This response was abrogated in mutant Akt lines, wherein it was presumed that PA indirectly affects Akt localization, and, therefore, activity, through its ability to modulate phosphoinositide 3-kinase (Lim et al., 2003) . Notably, macrophages infected with either the wild type or plasmid-cured strain of R. equi have very similar cytokine production profiles, suggesting that Akt is likely not the primary regulatory target of VapA (Giguere and Prescott, 1998) . While PA has an indirect effect on Akt, the lipid has been found to directly interact with mTOR via the FRB domain (Fang et al., 2001; Frondorf et al., 2010) . mTOR works in conjunction with the V-type ATPase on lysosomal membranes to sense available nutrients inside the phagosome (Flinn et al., 2010; Zoncu et al., 2011) . Thereafter, mTOR mediates downstream signaling events to alter protein synthesis and autophagic pathways (Flinn et al., 2010) . Lastly, experiments studying phagocyte chemotaxis have shown that PA stimulates S6K to promote cellular migration through a Transwell plate, and, therefore, likely promotes the migration of phagocytes into infected tissues (Frondorf et al., 2010) . Accordingly, the VapA:PA interaction could have drastic effects on a number of PA-dependent cellular physiologies, wherein modulation of the mTOR or S6K proteins later in the Akt-mTOR-S6K signaling cascade is one such example.
While we found that rVapA 32-189 interacted with PAcontaining liposomes, neither of the pVapB encoded Vaps tested, rVapB or rVapK2 , bound PA liposomes to levels observed with rVapA 32-189 (Fig. 5D ).
R. equi isolates carrying alternate virulence plasmids differ in their disease presentation and host species tropism; wherein equine isolates, carrying exclusively pVapA, present with pyogranulomatous pneumonia and swine isolates, carrying primarily pVapB, show submaxillary lymphadenitis (Takai et al., 1996; Makrai et al., 2005; Komijn et al., 2007; Giguere et al., 2011) . It has been determined, however, that R. equi equipped with either the pVapA or pVapB type virulence plasmids can replicate within macrophages of many species; showing that interspecies macrophage differences are not responsible for the plasmid-specific species tropism observed (Willingham-Lane et al., 2016) . It has been presumed that the Vaps responsible for supporting the intramacrophage growth of differing R. equi isolates would employ similar molecular mechanisms during pathogenesis. Here, we have shown that while rVapK2 32-202 supplementation rescues the intramacrophage growth phenotype of DvapA R. equi and that GFP-VapK2 32-202 to some extent localizes to the yeast plasma membrane, the protein was not detected to interact with PA (Figs. 1C, 1D and 6D ). While it is likely that the core structures of the Vap proteins are conserved (Geerds et al., 2014; Whittingham et al., 2014; Okoko et al., 2015) , it is possible that rVapK2 cooperates with a different lipid in the eukaryotic membrane. Alternatively, rVapK2 32-202 may lack the capacity to interact with PA, but contains a shared function with VapA that has yet to be determined. Future work is required to elucidate or eliminate the possibility of lipid binding by rVapK2. It should be noted that the bulk of research on R. equi pathogenesis has focused on pVapA carrying isolates, as these are typical of strains derived from both diseased horses and humans. It is, therefore, unknown if the R. equi-containing vacuole generated by strains harboring the pVapB-type virulence plasmid follows the same phagolysosomal maturation process as those strains harboring the pVapA-type plasmid (Fernandez-Mora et al., 2005; Toyooka et al., 2005; von Bargen et al., 2009 ). This represents a gap in the knowledge regarding macrophage infection with R. equi and should be considered when addressing R. equi virulence in the future. In closing, the identification of VapA:-host membrane and VapA:PA interactions define a new understanding of VapA:host molecular interactions that should provide insight into the activity of VapA during R. equi pathogenesis. Future work will identify the region of VapA responsible for PA binding, and may help answer the question of why the other highly homologous Vap proteins of R. equi are insufficient to support intramacrophage replication in the absence of the VapA protein.
Experimental procedures

Bacterial and yeast cells
Bacterial and yeast strains used in these studies are listed in Table 1 . Escherichia coli was grown in Luria-Bertani (LB) broth at 378C with antibiotics where appropriate. Selective antibiotics used for E. coli were carbenicillin or hygromycin at 50 mg ml 21 or 180 mg ml 21 respectively. R. equi was grown in Brain Heart Infusion (BHI) broth at 378C or 308C and supplemented with either 80 mg ml 21 apramycin or 180 mg ml 21 hygromycin, when appropriate. Saccharomyces cerevisiae strain BY4742 cells were grown on yeast extract peptone dextrose (YPD) agar or broth at 308C. BY4742 cells transformed with a plasmid that conferred auxotrophic selection through uracil were grown at 308C and either plated on or in complete supplemental mixture lacking uracil.
Recombinant Vap purification
Plasmids utilized and constructed in this study are shown in Supporting Information Table S1 . Vap proteins were cloned into the pHis-Parallel1 overexpression plasmid (Sheffield et al., 1999) as follows: Vap open reading frames were amplified from the respective virulence plasmid templates (103S plasmid for vapA and vapG; 33705 plasmid for vapB and vapK2) using the primers listed in Supporting Information Table S2 . These primers only amplify the part of the vap gene that is responsible for the disordered and conserved domains of the proteins, and lack the putative Nterminal signal sequences; accession numbers for proteins are CAQ30407 (VapA), CAQ30394.1 (VapG), CAQ30336.1 (VapK2) and CAQ30339.1 (VapB) (Letek et al., 2008) . Amplicons were digested using the appropriate restriction enzymes underlined in Supporting Information Table S2 and cloned into pHis-Parallel1, which had been digested with the same enzymes. Resultant plasmids, pVapALMW, pVapGLMW, pVapBLMW and pVapK2LMW, were confirmed by sequencing at the Georgia Genomics Facility (University of Georgia).
Plasmids expressing N-terminal hexahistidine fusions to Vap proteins were electroporated into the E. coli Tuner TM strain (EMD Millipore). Acquired transformants were grown to an OD 600 5 0.8-1.0 at 378C in LB supplemented with carbenicillin. His-Vap expression was induced with 1 mM isopropyl b-D-1-thiogalactopyranoside and cells were grown for another 4 h at 378C with shaking. Cells were harvested and suspended in lysis buffer [1 ml 0.5 g 21 wet weight pellet; 50 mM sodium phosphate pH 7.0, 300 mM NaCl, 10 mM imidazole, 1 mg ml 21 lysozyme, 1 mM bmercaptoethanol, and EDTA-free protease inhibitor cocktail VapA of R. equi binds phosphatidic acid 439 (Thermo Scientific)]. Cell mixture was incubated for 1 h at room temperature with gentle agitation, and sonicated to disrupt cells (6 3 30 s).
Lysed cells were clarified via centrifugation (19 000 3 g, 15 min, 48C), and passed over Ni-NTA resin, which had been pre-equilibrated with lysis buffer lacking protease inhibitors, lysozyme, and b-mercaptoethanol. The resin was washed once each with 10 column volumes wash buffer (50 mM sodium phosphate pH 7.0 and 300 mM NaCl) containing increasing amounts of imidazole (20 mM, 40 mM, 60 mM). Protein was eluted with wash buffer containing 500 mM imidazole. Eluted protein was dialyzed into 50 mM potassium phosphate pH 7.4, 150 mM KCl, and 10% (v/v) glycerol, and stored at 2808C.
Proteinase K digestion of recombinant Vap proteins
Vap proteins were digested by Proteinase K (Novagen) in a 500:1 (protein:enzyme) mass ratio as described by Geerds and colleagues (2014) . Briefly, Proteinase K and Vap proteins were incubated either with or without 1% SDS at 378C for 75 min. Digestion was halted by addition of 2 mM phenylmethanesulfonyl-fluoride (PMSF) and resulting products were run on an SDS-PAGE gel.
Construction of yeast expressing GFP tagged Vaps
To generate GFP-VapA yeast expression constructs, primer pairs GFP-VapA SS F and GFP-VapA R or GFP-VapA NSS F and GFP-VapA R were used to amplify the open reading frames from103S corresponding to VapA or VapA respectively. The remaining vap genes were amplified using their respective GFP-Vap(X) NSS F and GFP-Vap(X) R primers from either the 103S or 33705 plasmid; wherein a region containing vapL-M from 33705 was initially amplified to PCR vapK2. The resultant PCR products from these primers (Supporting Information Table S2 ) provided sequence homology to the pGO35 vector, which allows for the constitutive expression of an N-terminally GFP tagged protein of interest (a gift from Alexey Merz, UW Seattle) (Burd and Emr, 1998; Odorizzi et al., 1998) . pGO35 was digested with BglII, and co-transformed with the corresponding amplicons via standard lithium acetate methods (Gietz and Woods, 2002) 
SDS-PAGE and Western blotting
Pure protein samples were boiled for 8 min in 1 3 loading dye consisting of 50 mM Tris-Cl (pH6.8), 2% SDS, 0.1% (w/v) bromophenol blue, 10% glycerol, and 100 mM DTT. For extracting protein from whole yeast cells, approximately 1 3 10 9 cells were suspended in 200 ml lysis buffer (0.1 M NaOH, 0.05 M EDTA, 2% SDS, and 2% b-mercaptoethanol) before boiling for 10 min. Afterwards, 5 ml of 5 M glacial acetic acid was added to the yeast lysates before vortexing for 30 s and boiling samples for an additional 10 min. Yeast samples then had loading dye added to a 1 3 concentration.
Prepped samples were run on an SDS-PAGE gel in 1 3 Tris-Glycine SDS running buffer (NovexV R ). Transfer of the samples from the SDS-PAGE gel to a nitrocellulose membrane was done in a 1.4% (w/v) glycine, 0.3% (w/v) Tris Base, and 20% methanol buffer. Thereafter, the nitrocellulose membrane was blocked using the SuperBlockV R T20 (TBS) blocking buffer (Thermo Scientific) for either an hour at room temperature or overnight at 48C with agitation. Primary polyclonal rabbit aVapA was diluted 1:1000 in blocking buffer. Primary antibodies were then incubated with the membrane for either 1 h at room temperature or overnight at 48C with agitation. Afterwards, while rocking, the membrane was washed 4 3 for 10 min each with a .05% (v/v) Tween 20 and 1 3 PBS solution. Thereafter, secondary goat arabbit antibody, conjugated to horseradish peroxidase (HRP), was diluted 1:20 000 in blocking buffer and incubated with the membrane as done with the primary antibody. Next, the membrane was washed as done previously. To expose the western blot, enhanced chemiluminescent HRP substrate and peroxide buffer, both from Thermo Scientific, were mixed and added to the membrane and allowed to incubate at room temperature for 5 min.
Electroporation of R. equi
An overnight 100 ml culture of DvapA R. equi in BHI broth was diluted to an OD 600 of 0.4 with fresh medium, and grown at 308C until it reached an OD 600 of 0.8-1.0. Bacteria were harvested via centrifugation (3600 3 g, 10 min, 48C), the pellet was washed with 50 ml of cold sterile dH 2 O, and centrifuged for an additional 30 min. This wash step was repeated and additional time, then cells were suspended in 4 ml cold, sterile dH 2 O water containing 5% glycerol. Approximately 200 ng pGFPmut2 DNA was added to 400 ml of washed bacteria and mixed by gentle pipetting. The bacteria/DNA mixture was then placed in a pre-chilled 2 mm electroporation cuvette (Bio-Rad) and electroporated (2500 V, 25 mF, 1000 X). Immediately following electroporation, 1 ml of filter sterilized BHI supplemented with 0.5 M sucrose was added to the cuvette, collected and incubated for one hour at 308C. Following incubation, bacteria were harvested via centrifugation, 400 ml of the supernatant was discarded, and the bacterial pellet was suspended in the remaining supernatant. Aliquots of the resuspension were then plated to appropriate selective media, and incubated at 308C for two days.
Macrophage growth conditions and isolation
J774A.1 macrophages (ATCC) were grown at 378C with 5% CO 2 in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat inactivated Fetal Bovine Serum (FBS) and 2 mM glutamine (complete medium).
BMDM were isolated from femurs and tibias of BALB/c mice (Jackson Laboratories). To isolate BMDM precursors, femurs and tibias were dissected from the mouse and flushed with cold cation-deficient 13 PBS containing 100 units ml 21 penicillin and 10 mg ml 21 streptomycin (P/S). Cells retrieved from the bone marrow were centrifuged (260 3 g, 10 min, 48C), washed once with complete media containing P/S, then suspended in complete media supplemented with P/S and 10% supernatant from Colony Stimulating Factor-1 (CSF-1) producing L929 cells (24 ml per mouse). These precursor cells were incubated in 6-well non-tissue culture treated plates (378C, 5% CO 2 ; 4 ml suspended cells per well) for 3 days. After incubation, 4 ml complete media containing 10% L929 cell supernatant (no P/S) were added to each well and incubation continued. On days five and six, all of the media on the cells was removed and replaced with complete media supplemented with 10% CSF-1 containing L929 cell supernatant. Following a 2 h incubation with the fresh media on day six, the media was removed from the wells and replaced with cold 13 PBS, incubated at 48C for 10 min, and macrophages were harvested. Macrophages obtained were either used immediately in assays, or suspended in 90% FBS with 10% DMSO at 5 3 10 6 cells per ml and frozen in liquid nitrogen. For assays, cells were maintained in DMEM supplemented with 10% FBS, 2 mM glutamine, and 10% L929 cell supernatant containing CSF-1.
Macrophage infection assays
1 3 10 5 macrophages were placed on 13 mm-diameter glass coverslips or in 24-well tissue culture plates. When applicable, filter sterilized recombinant protein was suspended in macrophage media at a concentration of 50-150 nM and incubated with the monolayer overnight. The next morning, monolayers were washed with complete media. Bacteria, suspended in PBS, were added to the monolayer at a multiplicity of infection of 5:1 (J774A.1) or 7:1 (BMDM) during R. equi infections or 10:1 during E. coli infections. After 1 h, the monolayer was washed three times with warm DMEM without supplementation. The monolayers were maintained in complete media supplemented with 20-40 mg ml 21 amikacin to kill any remaining extracellular bacteria; while one plate was lysed for bacterial quantification at T1.
To quantify R. equi loads in macrophages, cells were lysed (378C, 5% CO 2 , 20 min) with 500 ll of sterile dH 2 O. For E. coli infections, 500 ml 0.5% (v/v) Triton X-100 was added to macrophages, and the incubation time was reduced to 5 min. The resultant lysates containing bacteria were collected, serially diluted in PBS, and plated on BHI (R. equi) or LB (E. coli) agar and incubated at 378C for 24-48 h. For later time points, the monolayer was washed three times with DMEM, as before, and the lysis procedure was performed.
Immunofluorescence assays
Infected macrophage monolayers on 13 mm diameter coverslips in 24-well plates were fixed with 4% (v/v) paraformaldehyde in PBS (228C, 20 min, in the dark). Coverslips were washed four times with PBS supplemented with 5% FBS, and fixed cells were permeabilized with 350 ll of PBS containing 0.1% Triton X-100 (3 min). 250 ll anti-VapA polyclonal antibody (diluted 1:1600 in PBS with 5% FBS and 0.1% (v/v) Triton X-100) was incubated on the coverslips for one hour in the dark at 228C. Coverslips were washed four times in PBS supplemented with 5% FBS and 0.1% (v/v) Triton X-100. Afterwards, 250 ll goat anti-rabbit antibody conjugated to fluorescein isothiocyanate (FITC) (1:500 in PBS with 5% FBS and 0.1% (v/v) Triton X-100, Thermo Scientific), was incubated with the fixed monolayer and washed, as above. 250 ll of an a-LAMP1 mouse monoclonal conjugated to Alexa Fluor 647 (diluted 1:500 in PBS with 5% FBS and 0.1% (v/v) Triton X-100) was used to stain monolayers for LAMP1 as described for the aforementioned primary and secondary antibodies. Washing was completed as done previously. A final wash with with PBS was immediately performed before the coverslips were mounted on microscope slides using ProLong Gold antifade reagent with 4 0 ,6-diamidino-2-phenylindole (DAPI) (ThermoFisher Scientific), and were allowed to dry for 24 h before visualization via confocal microscopy.
Liposome production
Stock 16:0-18:1 phospholipids (Avanti Polar Lipids) were dissolved in chloroform and mixed in glass tubes to provide a final amount of 2 mmol total lipid. For quantification, 0.5% (mol/mol) rhodamine-phosphatidylethanolamine (Rh-PE) was added to all mixtures. Lipid mixtures were composed of 1-palmitoyl-2-oleoylsn-glyceryo-3-phosphocholine (POPC) and either 1-palmitoyl-2-oleoyl-sn-glyceryo-3-phosphate (POPA), 1-palmitoyl-2-oleoyl-snglyceryo-3-phosphoethanolamine (POPE), or 1-palmitoyl-2-oleoyl-sn-glyceryo-3-phospho-L-serine (POPS) were added to the indicated percentage. Chloroform was removed via a stream of argon gas, and complete solvent removal was obtained under vacuum for 1 h. Dried lipids were suspended in 1 ml buffer containing either 20 mM 4-2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4 or 50 mM 2-ethanesulfonic (MES) and 3-(N-morpholino)propanesulfonic (MOPS) acid pH 5.5, depending on the pH desired, 10% (v/v) glycerol, and 150 mM NaCl. The suspended lipids were placed in a 378C water bath and intermittently vortexed at high speed for 60 min. After 10 freeze-thaw cycles in liquid nitrogen, suspended lipids were passaged 11 times through a Mini-Extruder (Avanti Polar Lipids) fitted with a 1 mm polycarbonate membrane, which had been previously equilibrated on a heating block set to 378C.
Liposome quantification was determined with the use of a Rh-PE standard curve in RB150 (20 mM HEPES pH 7.4 or 50 mM MES pH 5.5, 150 mM NaCl, 10% (v/v) glycerol) containing 1% (v/v) Thesit; liposomes of interest were also serially diluted in this same buffer. Fluorescence of the suspensions was determined by loading 20 ml each suspension into a 384-well, low-volume, black microplate (Corning) and a computer-controlled multimode plate reader (k ex 5 540 nm, k em 5 585 nm; BioTek). Liposomes were stored at 48C until the time of assay.
Liposome floatation 50 ml reactions containing 500 mM total lipids and 1 mg of recombinant protein of interest were incubated for 1 h in a VapA of R. equi binds phosphatidic acid 441 378C water bath. Afterwards, 5 ml of the reaction was collected as a control before adding 50 ml of 80% filtersterilized Histodenz (Sigma Aldrich) in the appropriate pH RB150 buffer. This mixture was inverted to mix, and placed into a 7 3 20 mm polycarbonate centrifuge tube (Beckman Coulter). Sampled were then overlaid with 75 ml of filter sterilized 30% Histodenz in RB150 and 75 ml of RB150 media. Samples were centrifuged (96 000 3 g for 2 h at 48C) before collecting 40 ml of the floated liposomes. To analyze the samples, the harvested liposome concentrations were determined via Rh-PE fluorescence, equivalent amounts of liposomes were separated via SDS-PAGE, and immunoblotted for Vap proteins.
Confocal microscopy
Fluorescence images were captured on a Nikon A1R confocal microscope system (UGA College of Veterinary Medicine Cytometry Core Facility) using a 1003 1.45NA (Nikon) objective, equipped with an S-P 50 mW multiline Ar laser for imaging GFP and Alexa 488 TM , a Coherent Sapphire 561 nm 20 mW laser for imaging dsRed, and a Coherent Cube 640 nm 40 mW laser for imaging Alexa 647 TM . Images were captured using NIS Elements software and processed with the Fiji (ImageJ v. 1.48) software package (Schindelin et al., 2012; Schneider et al., 2012) .
Statistical analysis
Sigma Plot version 11.2.0.5 (Systat Software, San Jose, CA) and GraphPad Prism version 6.0b (GraphPad Software, La Jolla, CA) were used for statistical analysis. Bacterial quantification was evaluated via a two-way analysis of variation (ANOVA) using the Holm-Sidak method, where a P value of 0.05 was considered significant.
